Labcorp Declares Quarterly Cash Dividend, Signals Ongoing Confidence
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Labcorp Holdings ( (LH) ) has issued an announcement.
Labcorp Holdings Inc., a global leader in laboratory diagnostics and drug development services, provides testing and scientific insights to healthcare providers, pharmaceutical firms, researchers and patients in roughly 100 countries, with nearly 71,000 employees and a major role in supporting new FDA-approved therapies. The company’s scale and reach position it as a critical infrastructure player in the global healthcare and life sciences ecosystem.
On April 9, 2026, Labcorp announced that its Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock. The dividend, payable on June 11, 2026 to shareholders of record as of May 29, 2026, underscores the company’s ongoing capital return strategy and may signal confidence in its financial performance and cash generation to investors.
The most recent analyst rating on (LH) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Labcorp Holdings stock, see the LH Stock Forecast page.
Spark’s Take on LH Stock
According to Spark, TipRanks’ AI Analyst, LH is a Neutral.
The score is driven primarily by solid (but uneven) financial performance and a constructive earnings outlook with guided growth, backlog strength, and margin initiatives. These positives are partially offset by a weak technical trend and only average valuation support, while recent financing-related corporate actions are modestly positive but keep leverage in focus.
To see Spark’s full report on LH stock, click here.
More about Labcorp Holdings
Labcorp Holdings Inc., listed on the NYSE as LH, is a global provider of innovative and comprehensive laboratory services serving doctors, hospitals, pharmaceutical companies, researchers and patients. The company leverages extensive diagnostics and drug development capabilities, employs nearly 71,000 people in about 100 countries, supported 85% of FDA drug and therapeutic approvals in 2025 and performs over 750 million tests annually worldwide.
Average Trading Volume: 698,465
Technical Sentiment Signal: Strong Buy
Current Market Cap: $22.64B
See more insights into LH stock on TipRanks’ Stock Analysis page.
